Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Gallacher Capital Management LLC

Gallacher Capital Management LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 85.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,403 shares of the biopharmaceutical company’s stock after acquiring an additional 5,245 shares during the period. Gallacher Capital Management LLC’s holdings in Halozyme Therapeutics were worth $421,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of HALO. International Assets Investment Management LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at $1,030,000. Harvey Capital Management Inc. acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $5,918,000. Hsbc Holdings PLC grew its position in shares of Halozyme Therapeutics by 35.0% during the third quarter. Hsbc Holdings PLC now owns 78,404 shares of the biopharmaceutical company’s stock worth $3,006,000 after acquiring an additional 20,346 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Halozyme Therapeutics by 174.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock valued at $33,894,000 after acquiring an additional 563,989 shares during the period. Finally, Aurora Investment Counsel purchased a new stake in Halozyme Therapeutics in the 3rd quarter valued at $1,347,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total value of $384,900.00. Following the sale, the senior vice president now directly owns 168,176 shares in the company, valued at $6,473,094.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 30,000 shares of company stock valued at $1,196,800. 2.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, April 30th. The Goldman Sachs Group dropped their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. JMP Securities reissued a “market outperform” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. TheStreet cut shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. Finally, StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.29.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded up $0.09 during mid-day trading on Friday, reaching $39.91. The stock had a trading volume of 902,802 shares, compared to its average volume of 866,867. Halozyme Therapeutics, Inc. has a 12-month low of $29.85 and a 12-month high of $45.00. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The business has a 50-day simple moving average of $39.99 and a 200 day simple moving average of $37.91. The company has a market cap of $5.07 billion, a P/E ratio of 18.91, a price-to-earnings-growth ratio of 0.47 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.